GH Research (NASDAQ:GHRS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of GH Research (NASDAQ:GHRS) from a sell rating to a hold rating in a research note released on Saturday morning.

Several other equities research analysts have also commented on GHRS. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research note on Friday, July 17th. Guggenheim lifted their price target on GH Research from $34.00 to $40.00 and gave the company a “buy” rating in a report on Friday. HC Wainwright decreased their price objective on GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Needham & Company LLC raised their target price on GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Cantor Fitzgerald lifted their target price on GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday. Ten analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.00.

GH Research Stock Down 2.4%

GHRS stock opened at $29.53 on Friday. GH Research has a fifty-two week low of $11.32 and a fifty-two week high of $31.44. The firm’s 50-day simple moving average is $25.79 and its 200 day simple moving average is $20.28. The stock has a market cap of $2.03 billion, a PE ratio of -29.53 and a beta of 1.29.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.06. Equities analysts forecast that GH Research will post -1.42 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

Several large investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its stake in shares of GH Research by 43.1% during the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after acquiring an additional 780 shares during the period. Barclays PLC raised its holdings in GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after purchasing an additional 822 shares in the last quarter. North Star Investment Management Corp. acquired a new stake in GH Research in the first quarter worth approximately $31,000. Osaic Holdings Inc. lifted its position in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the period. Finally, Jefferies Financial Group Inc. boosted its stake in GH Research by 0.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after purchasing an additional 2,988 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.